Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries CincyTech-backed Eikonoklastes Therapeutics receives FDA approval for first-in-class ALS treatment By: Cincinnati Business Courier via Business Journals November 09, 2022 at 11:20 AM EST Eikonoklastes Therapeutics, a Cincinnati biotech startup developing a first-in-class treatment for ALS, otherwise known as Lou Gehrig’s Disease, received FDA approval. Read More >> Related Stocks: Harbor Disruptive Innovation ETF Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
CincyTech-backed Eikonoklastes Therapeutics receives FDA approval for first-in-class ALS treatment By: Cincinnati Business Courier via Business Journals November 09, 2022 at 11:20 AM EST Eikonoklastes Therapeutics, a Cincinnati biotech startup developing a first-in-class treatment for ALS, otherwise known as Lou Gehrig’s Disease, received FDA approval. Read More >> Related Stocks: Harbor Disruptive Innovation ETF